Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
E2TJ7zNDPQxuFbUK
Listen
